Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy - Scorecard - MDSpire

Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

  • By

  • Cole Friedes

  • Melanie Berger

  • Lauren Linkowski

  • Casey Hollawell

  • Harper Hubbeling

  • Daniel Alexander

  • Goldie Kurtz

  • Robert A. Lustig

  • Jay F. Dorsey

  • Arati S. Desai

  • Richard E. Phillips

  • Steven Brem

  • Christos Davatzikos

  • MacLean Nasrallah

  • Donald M. O’Rourke

  • Christina Jackson

  • Nduka M. Amankulor

  • Michelle Alonso-Basanta

  • Suyash Mohan

  • Stephen J. Bagley

  • Emily S. Lebow

  • April 25, 2026

  • 0 min

Share

Clinical Scorecard: Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

At a Glance

CategoryDetail
Condition
Key MechanismsPrognostic factors include MGMT promoter methylation, extent of resection, patient age, and radiation-induced lymphopenia.
Target Population
Care Setting

Key Highlights

  • Real-world data shows survival outcomes inferior to clinical trials, emphasizing the need for contemporary prognostic models.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • C
      • o
      • m
      • p
      • l
      • e
      • t
      • e
      • b
      • l
      • o
      • o
      • d
      • c
      • o
      • u
      • n
      • t
      • s
      • t
      • o
      • a
      • s
      • s
      • e
      • s
      • s
      • l
      • y
      • m
      • p
      • h
      • o
      • c
      • y
      • t
      • e
      • c
      • o
      • u
      • n
      • t
      • s
      • b
      • e
      • f
      • o
      • r
      • e
      • a
      • n
      • d
      • a
      • f
      • t
      • e
      • r
      • r
      • a
      • d
      • i
      • o
      • t
      • h
      • e
      • r
      • a
      • p
      • y
      • ,
      • i
      • d
      • e
      • a
      • l
      • l
      • y
      • a
      • t
      • b
      • a
      • s
      • e
      • l
      • i
      • n
      • e
      • a
      • n
      • d
      • a
      • t
      • r
      • e
      • g
      • u
      • l
      • a
      • r
      • i
      • n
      • t
      • e
      • r
      • v
      • a
      • l
      • s
      • d
      • u
      • r
      • i
      • n
      • g
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • .

      Risks

        Patient & Prescribing Data

        Adults with high-grade glioblastoma, IDH-wildtype.

        Treatment includes maximal safe resection, radiotherapy, and potentially temozolomide.

        Clinical Best Practices

        • Utilize modern radiotherapy techniques to optimize treatment outcomes.
        • Monitor for radiation-induced lymphopenia and adjust treatment accordingly.
        • Incorporate molecular profiling in treatment planning.

        References

        Original Source(s)

        Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

        • by Cole Friedes, Melanie Berger, Lauren Linkowski, Casey Hollawell, Harper Hubbeling, Daniel Alexander, Goldie Kurtz, Robert A. Lustig, Jay F. Dorsey, Arati S. Desai, Richard E. Phillips, Steven Brem, Christos Davatzikos, MacLean Nasrallah, Donald M. O’Rourke, Christina Jackson, Nduka M. Amankulor, Michelle Alonso-Basanta, Suyash Mohan, Stephen J. Bagley, Emily S. Lebow

        • April 25, 2026

        Related Content

        PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

        Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

        Synthetic short RNA in cancer